Targeting MSLN fully humanized antibody or antibody fragment and chimeric antigen receptor and application thereof
Through the whole human antibody fragments and chimeric antigen receptor technology targeting MSLN, CAR-NK cells were constructed, which solved the problems of poor prognosis and high recurrence rate of ovarian cancer treatment, and achieved efficient killing of MSLN overexpressed tumor cells. Significantly improves the therapeutic effect.
Patent Information
- Application Number
- CN202410935907.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-12
AI Technical Summary
The existing treatment methods for ovarian cancer have poor prognosis, high recurrence rate, and lack effective drug treatment options. Especially in patients with advanced cancer, chemotherapy has severe side effects and poor treatment effect.
Develop all-human antibodies or antibody fragments targeting MSLN and their chimeric antigen receptors. Through CAR-NK cell technology, enhance the killing ability of MSLN overexpressing tumor cells, and use chimeric antigen receptor technology to engineer in NK cells. The human antibody fragments that integrate MSLN-bound are synthesized and expressed to form CAR-NK cells, achieving efficient killing of MSLN-expression-related tumors.
It provides antibodies that bind to MSLN protein, significantly improves the killing effect on MSLN overexpressing tumor cells, prolongs the half-life of CAR-NK cells, avoids the problem of overactivation in CAR-T technology, and achieves better results. tumor cell killing effect.
Smart Images

Figure CN118909127A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a fully human antibody or antibody fragment targeting MSLN and a chimeric antigen receptor and application thereof. Background Art
[0002] Natural Killer (NK) cells are a key component of the innate immune system, and their cytotoxicity is regulated by a complex of multiple activating and inhibitory receptors, including natural cytotoxicity receptors (NCRs), NKG2D, CD16 (FcγRIIIa), FasL, TRAIL and other co-stimulatory receptors, such as LFA-1, CD244 (2B4) and CD137 (4-1BB), and inhibitory receptors including KIRs (killer cell immunoglobulin-like receptors) and NKG2A, etc. These receptors can recognize changes on the cell surface, thereby determining whether NK cells are activated. NK cells can quickly recognize and eliminate infected cells and tumor cells without prior sensitization. Therefore, genetic modification of allogeneic NK cells by chimeric antigen receptor (CAR) constructs can enhance the killing power and in vivo persistence of NK cells against tumor cells expressing specific antigens. In addition, compared with CAR-T therapy, CAR-NK therapy has higher safety.
[0003] Mesothelin (MSLN) is a glycosylphosphatidylinositol-linked membrane glycoprotein that is present at relatively low levels in mesothelial cells of the pleura, peritoneum, and pericardium of healthy individuals. However, MSLN is overexpressed in many different cancers, including mesothelioma, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, bile duct cancer, breast cancer, and ovarian cancer. The high expression of MSLN in various cancers and limited expression in normal tissues make it an attractive target for CAR-NK immunotherapy.
[0004] Ovarian cancer is the second most common gynecological tumor and has the highest mortality rate. Although combined chemotherapy is effective for patients with advanced cancer, the overall treatment effect is poor. Most patients experience severe chemotherapy side effects, and about 60% of patients relapse after receiving first-line chemotherapy. There are currently no other good drug treatment options. In order to solve the problem of poor prognosis and high recurrence rate of current treatment methods for ovarian cancer, it is urgent to explore new clinical treatment options to improve treatment effects. Summary of the invention
[0005] The object of the present invention is to provide a fully human antibody or antibody fragment targeting MSLN and a chimeric antigen receptor and application thereof. The fully human antibody or antibody fragment targeting MSLN can bind to human MSLN protein with high specificity, and experiments have shown that CAR-NK cells prepared based on the chimeric antigen receptor provided by the present invention can highly specifically target tumor cells overexpressing MSLN and achieve significant killing effects.
[0006] In order to achieve the above object, the present invention provides a fully human antibody or antibody fragment targeting MSLN, wherein the antibody or antibody fragment comprises: a heavy chain variable region and a light chain variable region;
[0007] The heavy chain variable region includes three complementary determining regions: HCDR1, HCDR2 and HCDR3, the amino acid sequence of the HCDR1 includes the sequence shown in SEQ ID NO: 3; the amino acid sequence of the HCDR2 includes the sequence shown in SEQ ID NO: 4; the amino acid sequence of the HCDR3 includes the sequence shown in SEQ ID NO: 5;
[0008] The light chain variable region includes three complementarity determining regions: LCDR1, LCDR2 and LCDR3, the amino acid sequence of LCDR1 includes the sequence shown in SEQ ID NO: 6; the amino acid sequence of LCDR2 includes the sequence shown in SEQ ID NO: 7; the amino acid sequence of LCDR3 includes the sequence shown in SEQ ID NO: 8.
[0009] Preferably, the MSLN binding domain of the antibody or antibody fragment is scFv, and the amino acid sequence of the scFv is the sequence shown in SEQ ID NO:1.
[0010] Preferably, the MSLN binding domain of the antibody or antibody fragment is scFv, and the nucleotide sequence of the scFv is the sequence shown in SEQ ID NO:2.
[0011] Another aspect of the present invention provides a chimeric antigen receptor, which contains the fully human antibody or antibody fragment targeting MSLN as described above.
[0012] Preferably, the chimeric antigen receptor comprises: a signal peptide sequence, a MSLN binding domain, a detection tag, a hinge region and a transmembrane domain, and a functional signal transduction domain connected in sequence;
[0013] The signal peptide sequence comprises CSF2RA or 2B4', the amino acid sequence of CSF2RA is the sequence shown in SEQ ID NO: 9, and the amino acid sequence of 2B4' is the sequence shown in SEQ ID NO: 10;
[0014] The detection tag comprises eGFP, and the amino acid sequence of the eGFP is the sequence shown in SEQ ID NO: 11;
[0015] The MSLN binding domain comprises scFv, and the scFv comprises the fully human antibody or antibody fragment targeting MSLN;
[0016] The hinge region comprises CD8', and the amino acid sequence of CD8' is the sequence shown in SEQ ID NO: 12;
[0017] The transmembrane domain comprises: any one of CD8", 2B4" or NKG2D, wherein the amino acid sequence of CD8" is the sequence shown in SEQ ID NO: 13, the amino acid sequence of 2B4" is the sequence shown in SEQ ID NO: 14, and the amino acid sequence of NKG2D is the sequence shown in SEQ ID NO: 15;
[0018] The functional signal transduction domain comprises: at least one of 2B4'", 4-1BB, DAP12, DAP10 and CD3 Zeta, the amino acid sequence of 2B4'" is the sequence shown in SEQ ID NO: 16, the amino acid sequence of 4-1BB is the sequence shown in SEQ ID NO: 17, the amino acid sequence of DAP12 is the sequence shown in SEQ ID NO: 18, the amino acid sequence of DAP10 is the sequence shown in SEQ ID NO: 19, and the amino acid sequence of CD3 Zeta is the sequence shown in SEQ ID NO: 20.
[0019] Another aspect of the present invention provides a host cell, wherein the host cell comprises the aforementioned chimeric antigen receptor.
[0020] Preferably, the host cell is a NK cell.
[0021] Another aspect of the present invention provides a lentiviral plasmid, which comprises a nucleotide sequence capable of encoding the aforementioned fully human antibody or antibody fragment targeting MSLN.
[0022] Use of the aforementioned fully human antibody or antibody fragment targeting MSLN, or the aforementioned chimeric antigen receptor, or the aforementioned host cell, or the aforementioned lentiviral plasmid in the preparation of anti-tumor drugs.
[0023] Preferably, the tumor is a tumor associated with overexpression of MSLN antigen.
[0024] Compared with the prior art, the beneficial effects of the present invention include at least:
[0025] (1) The fully human antibody or antibody fragment targeting MSLN provided by the present invention can bind to human MSLN protein with high specificity, and the EC50 value of the protein level of the lead antibody 2MH6 is 0.15nM. Further, chimeric antigen receptor technology (CAR) is used to engineer the expression of human antibody fragments that bind to MSLN integrated into CAR in NK cells, and the resulting CAR-NK cells can be used to treat hematological cancers associated with MSLN expression.
[0026] (2) The chimeric antigen receptor of the present invention has an intracellular signal transduction domain different from that of CAR-T technology, including NK cell endogenous gene proteins such as 2B4", DAP10, and DAP12. The chimeric antigen receptor of the present invention also has a combination of different structures and different signal transduction domains, which can better activate the targeted killing activity of NK cells while preventing overactivation of CAR-NK cells, prolonging the half-life, and achieving a better tumor cell killing effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The output results of three rounds of screening of single-chain scFv antibodies targeting MSLN.
[0028] Figure 2 ELISA was used to detect the binding of three rounds of phage library to MSLN protein.
[0029] Figure 3 ELISA test for the binding activity of candidate anti-MSLN fully human scFv antibodies to MSLN antigen protein.
[0030] Figure 4 This is the flow cytometry test result of the binding activity of the candidate anti-MSLN fully human scFv antibody to the cell surface MSLN antigen protein.
[0031] Figure 5 The expression rate of CAR on the surface of NK cells containing different anti-MSLN-CAR was detected by flow cytometry; wherein:
[0032] a represents the results of the FCARB group; b represents the results of the SCARA, SCARC, SCARD, SCARE, TCARF, TCARG, TCARH, and TCARI groups.
[0033] Figure 6 To detect the killing activity of NK cells containing different anti-MSLN-CARs against tumor cells SK-OV-3; wherein:
[0034] a represents the results of the FCARB group; b represents the results of the SCARA, SCARC, SCARD, SCARE, TCARF, TCARG, TCARH, and TCARI groups. DETAILED DESCRIPTION
[0035] Definition of terms
[0036] "Antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen binding portion thereof.Antibodies include single chain antibodies.
[0037] A "heavy chain" consists of a heavy chain variable region (VH) and a heavy chain constant region.
[0038] A "light chain" consists of a light chain variable region (VL) and a light chain constant region.
[0039] "scFv": single-chain antibody fragment, composed of the heavy chain variable region and light chain variable region of the antibody connected by a short peptide (linker) of 15 to 20 amino acids.
[0040] The "heavy chain variable region" and "light chain variable region" can be further subdivided into hypervariable regions, called "complementarity determining regions" (CDRs), which are interspersed in more conserved regions called "framework regions" (FRs). Each VH and VL consists of three CDRs and four FRs, which are arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that can interact with antigens. In the present invention, CDR1, CDR2, and CDR3 of the heavy chain variable region are represented as HCDR1, HCDR2, and HCDR3, respectively; CDR1, CDR2, and CDR3 of the light chain variable region are represented as LCDR1, LCDR2, and LCDR3, respectively.
[0041] The "constant region" may mediate the binding of the immunoglobulin to host tissues or factors.
[0042] An "antigen binding domain" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (eg, MSLN).
[0043] "Monoclonal antibody" refers to a preparation of antibody molecules consisting of a single molecule. A monoclonal antibody composition exhibits specific binding and affinity for a particular epitope (the portion of an antigen that is specifically recognized by an antigen receptor).
[0044] The "chimeric antigen receptor" is composed of an extracellular antigen binding region (composed of light chains and heavy chains derived from monoclonal antibodies, connected by a flexible hinge region in the middle to form a single-chain antibody), a transmembrane region and an intracellular signal transduction region.
[0045] "95-99% identity" refers to greater than 95% (optimally greater than 98%) homology.
[0046] "Modification" is a variant form of amino acids or nucleotides, including the deletion, insertion and / or substitution of one or more (usually 1 to 50, preferably 1 to 30, more preferably 1 to 20, and most preferably 1 to 10) amino acids or nucleotides, and the addition of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids or nucleotides at the C-terminus and / or N-terminus, but will not change the function of the protein or nucleic acid.
[0047] In this application, "anti-MSLN" and "targeting MSLN" are used interchangeably.
[0048] The present invention provides a fully human antibody or antibody fragment targeting MSLN, wherein the MSLN binding domain of the antibody or antibody fragment is scFv, and the amino acid sequence of the scFv is specifically shown in Table 1.
[0049] Table 1 Amino acid sequence of scFv
[0050]
[0051] The nucleotide sequence encoding scFv provided by the present invention includes the sequence shown in SEQ ID NO: 2. According to the codons corresponding to the bases in each sequence, after translation into an amino acid sequence, the corresponding amino acid sequence of scFv is the sequence shown in SEQ ID NO: 1. The sequences shown in SEQ ID NO: 3 to SEQ ID NO: 8 are the variable region sequences of SEQ ID NO: 1.
[0052] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0053] The sources of some materials are as follows:
[0054] MSLN antigen protein: Human MSLN, purchased from Kaixia, catalog number MSL-HM480B-100μg.
[0055] Phage antibody library of human single-chain antibody: constructed by Changzhou Felos Pharmaceutical Technology Co., Ltd.
[0056] Streptavidin magnetic beads: purchased from Invitrogen.
[0057] ELISA microplate: 96 half-well low-transparency flat-bottom microplate, purchased from Corning.
[0058] Anti-M13 HRP antibody: purchased from Thermo Fisher.
[0059] VCSM13 helper phage: purchased from Invitrogen.
[0060] SOC medium: purchased from Shanghai Biotechnology.
[0061] pCGMT3 phage vector: purchased from Addgene.
[0062] XL1-blue bacteria: purchased from Agilent, catalog number 200228.
[0063] LB solid medium plate: Dissolve 5 g yeast extract, 10 g peptone, 10 g sodium chloride and 10 g agar powder in 1 L of double distilled water, autoclave at 121°C, and then pour on the plate.
[0064] ABTS developer solution: purchased from Thermo Fisher, catalog number 002024.
[0065] Gelred nucleic acid dye: purchased from Thermo Fisher.
[0066] pFUSE expression vector: purchased from Invitrogen.
[0067] Plasmid extraction kit: purchased from QIAGEN.
[0068] Restriction endonucleases: purchased from Takara.
[0069] Recombinant enzyme: purchased from Novoprotein.
[0070] Lipo3000 reagent: purchased from Thermo Fisher.
[0071] Polybrene reagent: purchased from Thermo Fisher.
[0072] RMPI 1640 culture medium: purchased from Gibco.
[0073] DMEM culture medium: purchased from Gibco.
[0074] Myc-Tag (9B11) Mouse mAb (PE Conjugate): purchased from cell signaling company.
[0075] 293Fectin transfection reagent: purchased from Invitrogen, catalog number 12347500.
[0076] 293 Freestyle suspension cells: purchased from Thermo Fisher.
[0077] Immunoglobulin IgG1 constant region Fc segment: purchased from Nanjing GenScript Company.
[0078] BCA protein quantification kit: purchased from Pierce, catalog number 23252.
[0079] CBS antigen fixation solution: Dissolve 1.59 g Na2CO3 and 2.93 g NaHCO3 in 1 L water and adjust the pH to 9.6.
[0080] Anti-Human Fc HRP secondary antibody: purchased from Thermo Fisher.
[0081] 96-well transparent bottom plate: purchased from Corning.
[0082] Biacore instrument: purchased from GE, T200.
[0083] Protein A chip: purchased from GE.
[0084] Example 1 Screening of single-chain antibodies targeting human Mesothelin (MSLN)
[0085] (1) Establishment of a phage antibody library of fully human single-chain antibodies
[0086] Primers were designed to amplify the heavy chain variable region and light chain variable region of the fully human single-chain antibody, and the heavy chain variable region and the light chain variable region were connected by overlapping extension PCR using (GGGGS)3-Linker to obtain a full-length PCR product; the PCR product and the pCGMT3 phagemid vector were digested with SfiI, and the ligated transformation product was electroporated into XL1-blue competent cells after T4 ligase reaction at 16°C, and then 3 mL of SOC medium was added to the competent cells. After culturing at 30°C for 1 h, ampicillin at a final concentration of 50 μg / mL and tetracycline at 10 μg / mL were added, and the cells were shaken and cultured at 37°C for 2 h.
[0087] Then add a concentration of 10 13 / mL VCSM13 helper phage 50μL, incubate at room temperature for 1h, shake gently every 10min, and culture at 37°C for 2h, then add kanamycin with a final concentration of 70μg / mL, and culture at 30°C overnight; collect the supernatant by centrifugation, add 10% PEG-8000 / sodium chloride solution (PEG is polyethylene glycol), put it in an ice bath for 1h, centrifuge at 8000rpm and 4°C, discard the supernatant, use 2mL of PBS solution (phosphate buffer) containing 1% BSA (bovine serum albumin) to fully dissolve the precipitate, and collect the supernatant by centrifugation, which is the phage-displayed fully human single-chain antibody library.
[0088] (2) Screening of a fully human antibody library targeting MSLN antigen protein
[0089] Take 200 μL (containing 1×10 phage 13 / mL) of phage antibody library expressing fully human single-chain antibodies was mixed with 5 μg of His-tagged MSLN antigen protein, and 50 μL of streptavidin magnetic beads were added after incubation at room temperature for 2 hours. The phage bound to the antigen was captured by the streptavidin magnetic beads, and the unbound phage was removed after rinsing with 0.5% Tween-20 PBS solution (phosphate buffer), and the phage stably bound to the magnetic beads was eluted with hydrochloric acid glycine solution (pH 2.2) for standby use.
[0090] Inoculate 20 mL of XL1-Blue E. coli and shake the bacteria until the OD 600 (absorbance at 600 nm) reaches 0.6. Then add the eluted phages and incubate them with XL1-Blue E. coli at 37°C for 30 min. Spread the bacterial solution on an ampicillin-resistant plate. The next day, wash and collect the bacteria on the ampicillin-resistant plate. Infect 1×10 12 After adding pfu / mL (pfu, plaque forming unit) of VCSM13 helper phage, the next round of screening is carried out after amplification, and a total of 2-3 rounds of screening are carried out. The XL1-Blue bacterial solution that infects the input phage library (input) and the screened phage library (output) is fully diluted, and then the bacterial solution is spread on LB solid culture medium plates with ampicillin resistance, and the single clones on each plate are counted. The enrichment degree of the phage after screening is determined based on the counting results of output and input.
[0091] The results are as follows Figure 1As shown, after three rounds of panning targeting the His-tagged MSLN antigen protein, the output of the third round increased by more than 100 times compared to the output of the first round, and the output of the second round increased by more than 10 times. The monoclonal antibodies on the phage library (output) plate after screening were picked, and the phage libraries after each round of panning were verified by phage enzyme-linked immunosorbent assay.
[0092] (3) Enzyme-linked immunosorbent assay of phage library
[0093] The phage library (input) in each round was diluted 10-fold, 50-fold and 100-fold respectively, and the enzyme-linked immunosorbent microplate was coated with MSLN antigen protein at 4°C overnight, eluted with PBST (phosphate buffer containing Tween-20) and blocked, and then the above-diluted phage library (input) was added and incubated at room temperature for 2h. After washing the plate 8 times with PBST, Anti-M13 HRP antibody was added and incubated for 30min, and then washed 8 times with PBST, and 50μL of developing solution ABTS was added.
[0094] like Figure 2 As shown, according to OD 450 After three rounds of screening, the phage pools with different dilution ratios showed a significant increase in binding to the MSLN antigen, indicating that the screening targeting the human MSLN antigen obtained a significantly enriched antibody library.
[0095] (4) Monoclonal phage enzyme-linked immunosorbent assay
[0096] From the phage library obtained after the third round of screening, the XL1-Blue monoclonal bacteria that infect the phage were selected and inoculated into a 2mL 96-well bacterial culture plate (purchased from Corning), and 500μL of SB medium containing tetracycline resistance was added. The plate was shaken at 37°C for 4-6h at 200rpm. After the OD600 value was detected to be close to 0.6, 1μL of auxiliary phage was added, and the plate was shaken at 30°C overnight. The next day, the supernatant was taken for standby use at 3000g for 15 minutes. The enzyme-linked immunosorbent microplate was taken, coated with MSLN antigen protein at 4°C overnight, eluted with PBST (phosphate buffer containing Tween-20) and blocked, and then the prepared phage supernatant was added, incubated at room temperature for 2h, washed 8 times with PBST, and then Anti-M13 HRP antibody was added for incubation for 30min, and then washed 8 times with PBST, and 50μL of developing solution ABTS was added. According to the rule that OD450nm value>1 is determined as a positive clone, the positive clone is selected for sequencing to obtain the DNA sequence of the positive antibody, and the obtained sequence is compared and analyzed. The more repeated clones, the higher the enrichment degree of the antibody sequence, so as to determine the effectively enriched nucleotide coding sequence.
[0097] Example 2 Preparation of anti-MSLN single-chain antibody
[0098] (1) Expression and purification
[0099] The plasmid was extracted from the positive monoclonal strain screened in Experimental Example 1, and the fragment was ligated into the pFuse expression vector (the pFuse expression vector was acted on the restriction site by the restriction endonuclease SfiⅠ) by T4 ligase after being digested with the restriction endonuclease SfiⅠ, thereby obtaining the pFuse expression vector containing the anti-MSLN single-chain antibody.
[0100] The 293Fectin transfection reagent was mixed with the eukaryotic antibody expression vector obtained above at a volume-to-mass ratio of 30 μL:30 μg, 30 mL of 293Freestyle suspension cells were added, and the mixture was cultured at 37°C at 125 rpm for 48-72 hours. The supernatant was collected after centrifugation, and the antibody protein was purified on a protein purifier using Protein A HP columns to obtain purified anti-MSLN antibody test samples 2MG10, MD3, 2MC9, 2MD12, 2MC11, 2MH6, 2MD6, 2MB1, and MA8. Finally, the antibody concentration was detected according to the instructions of the BCA protein quantification kit.
[0101] Example 3 Detection of lead antibodies
[0102] (1) ELISA to detect the binding of antibodies to human MSLN protein
[0103] The purified anti-MSLN single-chain antibody prepared in Example 2 was tested for binding ability with human MSLN protein (purchased from Kaixia). The human MSLN protein was diluted with CBS antigen fixation solution to a final concentration of 1.0 μg / mL, and then added to a 96-well ELISA plate at 50 μL per well. The plate was sealed with plastic film and incubated overnight at 4°C. The next day, the plate was washed twice with a plate washing solution [PBS containing 0.01% (v / v) Tween20], and a blocking solution [PBS containing 0.01% (v / v) Tween20 and 1% (v / v) BSA] was added to block at room temperature for 1 hour. The blocking solution was discarded, and the purified human MSLN protein antibodies 2MG10, MD3, 2MC9, 2MD12, 2MC11, 2MH6, 2MD6, 2MB1, MA8 and negative control human Fc protein (hFc) prepared in Example 2 were diluted 3 times, with a starting concentration of 300nM, a total of 10 gradients, and added to the ELISA plate at 50μL per well. After incubation at 37°C for 1 hour, the plate was washed 8 times with a plate washing solution [PBS containing 0.01% (v / v) Tween20]. HRP (horseradish peroxidase) labeled rabbit anti-human IgG Fc secondary antibody was added, and after incubation at 37°C for 1 hour, the plate was washed 8 times with a plate washing solution [PBS containing 0.01% (v / v) Tween20]. 100μL of TMB substrate was added to each well, and after incubation at room temperature for 30 minutes, 100μL of stop solution (1.0N HCl) was added to each well. The A450nm value was read using a multifunctional microplate reader (SpectraMax iD5), and the EC50 value was calculated using a fitting curve.
[0104] The results are as follows Figure 3 As shown, the purified anti-MSLN single-chain antibody has specific binding ability with human MSLN recombinant protein at the ELISA level, and the lead antibodies 2MC9, 2MD12, 2MC11, 2MH6, 2MD6, 2MB1, and MA8 were selected for cell-level binding experiments. Among them, the EC50 of the lead antibody 2MH6 is 0.15nM, and the protein-level binding activity is good, which has the potential for further development.
[0105] (2) Flow cytometry (FACS) to detect the binding of antibodies to human MSLN overexpressing cells
[0106] The nucleotide sequence encoding the full-length human MSLN protein was cloned into the pLenti plasmid by homologous recombination, and the CHOK1 cell line was transfected to obtain a CHOK1 stable cell line overexpressing human MSLN (herein referred to as the CHOK1-hMesothelin stable cell line). The CHOK1-h4-1BB stable cell line was expanded and cultured in a 10 cm cell culture dish to 90% confluence, the culture medium was aspirated, and the cells were washed twice with FACS buffer. After the cells were collected for cell counting, the cells were diluted to 2×106 cells / ml, add 1% goat serum blocking solution, the percentage is mass percentage. Incubate on ice for 30 minutes, then centrifuge and wash twice with FACS buffer. The collected cells are suspended to 2×10 cells / ml with FACS buffer (PBS containing 1% BSA, the percentage is mass percentage). 6 cells / ml, 100 microliters per well were added to a 96-well FACS reaction plate, and the purified MSLN antibody test samples 2MC9, 2MD12, 2MC11, 2MH6, 2MB1, MA8 prepared in Example 2 and the negative control human Fc protein (hFC), and the positive control MSLN Tab1 protein were diluted 5 times, with a starting concentration of 200nM, a total of 7 gradients, 100 microliters of diluted test antibody was added to each well, and incubated on ice for 1 hour. Washed twice by centrifugation with FACS buffer, 100 microliters of fluorescent (Alexa 488) labeled sheep anti-human IgG Fc secondary antibody (purchased from Abcam) was added to each well, and incubated on ice for 1 hour. Washed 3 times by centrifugation with FACS buffer. Suspend the cells with 100 microliters of FACS buffer, detect and analyze the results with FACS (FACS Calibur, purchased from BD), and calculate the EC50 value with a fitting curve.
[0107] The results are as follows Figure 4 As shown, the purified anti-MSLN single-chain antibodies prepared in Example 2 can specifically recognize and bind to cells overexpressing MSLN protein on the cell surface, among which the EC50 of the lead antibody 2MH6 is 0.79nM, and the activity of specifically recognizing MSLN protein on the cell surface is high, and it has further development potential. The negative control is human Fc protein, and the data in the table are the average fluorescence intensity values of the cell population measured by MFI.
[0108] Example 4 Preparation of CAR-NK cells targeting MSLN
[0109] (1) Construction of different CAR structures containing human mesothelin single-chain antibody
[0110] The DNA fragment of the lead antibody 2MH6 obtained in Experimental Example 3 was inserted into the pCDH lentiviral vector to obtain a recombinant lentiviral vector pLenti-anti-MSLN-CAR. The anti-MSLN-CAR construct of the present invention comprises: EF-1α promoter, signal peptide sequence, MSLN binding domain, detection tag, hinge region and transmembrane domain, and functional signal transduction domain connected in sequence, expressed as: promoter-SP-scFv-hinge-TM-CD / s-SD-eGFP. Wherein:
[0111] The signal peptide sequence (SP) comprises CSF2RA (SP1) or 2B4' (SP2), the amino acid sequence of CSF2RA is the sequence shown in SEQ ID NO: 9, and the amino acid sequence of 2B4' is the sequence shown in SEQ ID NO: 10.
[0112] The detection tag comprises eGFP, and the amino acid sequence of the eGFP is the sequence shown in SEQ ID NO:11.
[0113] The MSLN binding domain comprises scFv, and the scFv comprises the fully human antibody or antibody fragment targeting MSLN.
[0114] The hinge region comprises CD8', and the amino acid sequence of CD8' is the sequence shown in SEQ ID NO:12.
[0115] The transmembrane domain (TM) comprises: any one of CD8", 2B4" or NKG2D, wherein the amino acid sequence of CD8" is the sequence shown in SEQ ID NO: 13, the amino acid sequence of 2B4" is the sequence shown in SEQ ID NO: 14, and the amino acid sequence of NKG2D is the sequence shown in SEQ ID NO: 15.
[0116] The functional signal transduction domain (CD / s-SD) comprises at least one of 2B4"', 4-1BB, DAP12, DAP10 and CD3 Zeta (CD3ζ), wherein the amino acid sequence of 2B4"' is the sequence shown in SEQ ID NO: 16, the amino acid sequence of 4-1BB is the sequence shown in SEQ ID NO: 17, the amino acid sequence of DAP12 is the sequence shown in SEQ ID NO: 18, the amino acid sequence of DAP10 is the sequence shown in SEQ ID NO: 19, and the amino acid sequence of CD3 Zeta (CD3ζ) is the sequence shown in SEQ ID NO: 20. .
[0117] In this example, 9 different anti-MSLN-CAR constructs were obtained through design and selection, as shown in the table below.
[0118] Table 2 9 different anti-MSLN-CAR constructs in Example 4
[0119] CARs Targeting Protein Construct (SP-scFv-hinge-TM-CD / s-SD) Label SCARA Mesothelin SP1-2MH6-CD8'-CD8”-4-1BB-CD3ζ eGFP FCARB Mesothelin SP2-2MH6-2B4"-2B4"' / SCARC Mesothelin SP1-2MH6-CD8'-CD8”-2B4”’-CD3ζ eGFP SCARD Mesothelin SP1-2MH6-CD8'-NKG2D-4-1BB-CD3ζ eGFP SCARE Mesothelin SP1-2MH6-CD8'-NKG2D-2B4”’-CD3ζ eGFP TCARF Mesothelin SP1-2MH6-CD8'-NKG2D-2B4″'-DAP10-CD3ζ eGFP TCARG Mesothelin SP1-2MH6-CD8'-NKG2D-2B4”’-DAP12-CD3ζ eGFP TCARH Mesothelin SP1-2MH6-CD8'-NKG2D-4-1BB-2B4”’-CD3ζ eGFP TCARI Mesothelin SP1-2MH6-CD8'-NKG2D-2B4”'-4-1BB-CD3ζ eGFP
[0120] (2) Packaging of lentivirus
[0121] 5 μg, 3.2 μg and 1.8 μg of the different recombinant lentiviral vectors pLenti-anti-Mesothelin-CAR, PspaX2 plasmid and PMD2.0G plasmid (PspaX2 plasmid and PMD2.0G plasmid are lentiviral packaging plasmids) prepared in step (1) were taken respectively, mixed and transfected into 293T cells (about 3×10 6 cells, 10 cm dishes, 10 mL of DMEM medium containing 10% (v / v) FBS), the virus stock solution was collected 72 hours after transfection, and different groups of CAR-NK lentivirus were obtained after filtering with a 0.45 μm filter membrane, and the titer was detected using a kit.
[0122] (3) Recombinant lentivirus infection of NK cells
[0123] To recover NK cells (isolated and cultured from peripheral blood), centrifuge at 300 g for 10 min after overnight culture, collect the cells and resuspend them in NK cell culture medium. Take a 12-well plate and add 5×10 5 NK cells, 100 μL CAR-NK lentivirus, polybrene and IL2 were mixed to obtain a culture system. In the culture system, the concentration of polybrene was 8 μg / mL, the concentration of IL2 was 500 U / mL, and the culture was placed in a 37°C, 5% CO2 incubator to obtain CAR-NK cells targeting mesothelin protein.
[0124] (4) Detection of CAR expression
[0125] Take 2×10 5 NK cells were washed twice with FACS buffer, incubated with fluorescently labeled MSLN detection protein, washed twice with FACS buffer, and the CAR expression rate was detected by flow cytometry.
[0126] The results are as follows Figure 5 As shown in Figures a and b, CAR-NK cells containing different anti-MSLN-CARs were prepared by lentiviral transfection, and the transfection efficiency ranged from 18% to 60%.
[0127] Example 5 Detection of the killing effect of CAR-NK cells targeting mesothelin on ovarian cancer tumor cells
[0128] The CAR-NK cells or human NK cells (isolated and cultured from peripheral blood) prepared in Example 4 were used as effector cells, and ovarian cancer tumor cells SKOV3 (product of ATCC) that highly expressed human MSLN protein were used as target cells to detect killing activity. 1×10 4ovarian cancer tumor cells SKOV3 were cultured and CAR-NK or human NK effector cells were added according to different effector-target ratios to obtain an incubation system. In the incubation system, the number of effector cells was 5×10 4 pcs, 2.5×10 4 pcs, 1×10 4 or 0.4×10 4 The cells were incubated at 37°C and 5% CO2 for 4 h. The DELFA kit was used to detect the killing efficiency of effector cells on ovarian cancer tumor cells (killing efficiency = number of viable cells of ovarian cancer tumor cells after incubation / 10 4 × 100%), and then draw a killing curve with the ratio of the number of effector cells to ovarian cancer tumor cells as the horizontal axis and the killing efficiency as the vertical axis.
[0129] The results are as follows Figure 6 As shown, compared with human NK cells, the CAR-NK cells containing different anti-MSLN-CARs prepared in Example 4 have better killing effects on ovarian cancer tumor cells SKOV3.
[0130] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.
Claims
1. A fully human antibody or antibody fragment targeting MSLN, characterized in that: The antibody or antibody fragment comprises: a heavy chain variable region and a light chain variable region; The heavy chain variable region includes three complementarity determining regions: HCDR1, HCDR2, and HCDR3, wherein the amino acid sequence of HCDR1 includes the sequence shown in SEQ ID NO: 3; the amino acid sequence of HCDR2 includes the sequence shown in SEQ ID NO: 4; and the amino acid sequence of HCDR3 includes the sequence shown in SEQ ID NO: 5; The light chain variable region includes three complementarity determining regions: LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 includes the sequence shown in SEQ ID NO: 6; the amino acid sequence of the LCDR2 includes the sequence shown in SEQ ID NO: 7; and the amino acid sequence of the LCDR3 includes the sequence shown in SEQ ID NO:
8.
2. The fully human antibody or antibody fragment targeting MSLN according to claim 1, characterized in that The MSLN binding domain of the antibody or antibody fragment is scFv, and the amino acid sequence of the scFv is the sequence shown in SEQ ID NO:
1.
3. The fully human antibody or antibody fragment targeting MSLN according to claim 1, characterized in that The MSLN binding domain of the antibody or antibody fragment is scFv, and the nucleotide sequence of the scFv is the sequence shown in SEQ ID NO:
2.
4. A chimeric antigen receptor, characterized in that The chimeric antigen receptor contains the fully human antibody or antibody fragment targeting MSLN according to any one of claims 1 to 3.
5. The chimeric antigen receptor according to claim 4, characterized in that The chimeric antigen receptor comprises: a signal peptide sequence, an MSLN binding domain, a detection tag, a hinge region and a transmembrane domain, and a functional signal transduction domain connected in sequence; The signal peptide sequence comprises CSF2RA or 2B4', the amino acid sequence of CSF2RA is the sequence shown in SEQ ID NO: 9, and the amino acid sequence of 2B4' is the sequence shown in SEQ ID NO: 10; The detection tag comprises eGFP, and the amino acid sequence of the eGFP is the sequence shown in SEQ ID NO: 11; The MSLN binding domain comprises scFv, and the scFv comprises the fully human antibody or antibody fragment targeting MSLN; The hinge region comprises: CD8', wherein the amino acid sequence of CD8' is the sequence shown in SEQ ID NO: 12; The transmembrane domain comprises any one of CD8", 2B4" or NKG2D, wherein the amino acid sequence of CD8" is the sequence shown in SEQ ID NO: 13, the amino acid sequence of 2B4" is the sequence shown in SEQ ID NO: 14, and the amino acid sequence of NKG2D is the sequence shown in SEQ ID NO: 15; The functional signaling domain comprises: at least one of 2B4″′, 4-1BB, DAP12, DAP10 and CD3 Zeta, wherein the amino acid sequence of 2B4″′ is the sequence shown in SEQ ID NO: 16, the amino acid sequence of 4-1BB is the sequence shown in SEQ ID NO: 17, the amino acid sequence of DAP12 is the sequence shown in SEQ ID NO: 18, the amino acid sequence of DAP10 is the sequence shown in SEQ ID NO: 19, and the amino acid sequence of CD3 Zeta is the sequence shown in SEQ ID NO:
20.
6. A host cell, characterized in that The host cell comprises the chimeric antigen receptor according to claim 4 or 5.
7. The host cell according to claim 6, characterized in that The host cell is a NK cell.
8. A lentiviral plasmid, characterized in that The lentiviral plasmid comprises a nucleotide sequence capable of encoding the fully human antibody or antibody fragment targeting MSLN according to any one of claims 1 to 3.
9. Use of the fully human antibody or antibody fragment targeting MSLN according to any one of claims 1 to 3, or the chimeric antigen receptor according to claim 4 or 5, or the host cell according to claim 6 or 7, or the lentiviral plasmid according to claim 8 in the preparation of anti-tumor drugs.
10. The use according to claim 9, characterized in that The tumor is a tumor associated with overexpression of MSLN antigen.
Citation Information
Patent Citations
Chimeric antigen receptor targeting MSLN and application of chimeric antigen receptor
CN111848819A
Chimeric antigen receptor specifically binding to MSLN and application thereof
CN116234911A
Chimeric antigen receptor comprising an antigen binding domain specific for MSLN having a specificity for tumor cells
US20230390393A1
Cited By
MSLN-specific chimeric antigen receptor, car-t cell and use thereof
WO2026118738A1
